BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...SIX:VIFN) for about $915 million; NeuroVir Therapeutics Inc., which was taken out in 2001 by Medigene AG...
BioCentury | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

...announced Thursday that its next-generation melanoma-associated antigen A4 (MAGEA4) TCR therapy, developed in collaboration with Medigene AG...
...single agent led to "robust" antitumor activity controlling tumors in a melanoma xenograft model (see "Medigene...
...bluebird gained $1.03 to $133.52 on Thursday. Mark Zipkin, Staff Writer Zynteglo (LentiGlobin BB305 gene therapy) bluebird bio Inc. Medigene AG...
BioCentury | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

...newco also obtained a license in Asian territories to four T cell immunotherapy programs from Medigene AG...
...targets that Cytovant has yet to choose, according to Medigene CEO and CSO Dolores Schendel. Medigene...
...billion in milestones across the four programs, plus low double-digit royalties. Cytovant will also reimburse Medigene's...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...U.K.) hired Markus Dangl as CSO. He was SVP for research and non-clinical development at Medigene AG...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...Jason Cole will assume the new and expanded role of chief operating and legal officer. Medigene AG...
BioCentury | Jan 11, 2019
Company News

Medigene licenses co-stimulator from Helmholtz to overcome checkpoint blockade with TCRs

...4-1BB ligand (4-1BBL; TNFSF9; CD137L), to help T cells overcome checkpoint blockade in solid tumors. Medigene...
...disclosed. Helmholtz Zentrum München, Neuherberg, Germany Medigene AG (Xetra:MDG1), Martinsried, Germany Business: Cancer Jennie Walters Helmholtz Zentrum Muenchen GmbH Medigene AG 4-1BB...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...to see if there is any effect on lipids in peripheral blood.” Ginna Laport, Tempest Medigene AG...
...Dracen Pharmaceuticals Inc., Baltimore, Md. Genfit S.A. (Euronext:GNFT), Loos, France Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Medigene AG...
BioCentury | Aug 31, 2018
Company News

Management tracks: Medigene, Merck KGaA

...Medigene AG (Xetra:MDG1) said CFO Thomas Taapken has resigned. Medigene is seeking a successor. Taapken, who...
...successor. Taapken, who joined the cancer immunotherapy company in January 2017, will continue to advise Medigene...
BioCentury | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

...R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd. (KOSDAQ:084990), Medigene AG...
...Prime Therapeutics Inc. (NASDAQ:FPRX). Three of the deals -- those with Celgene, TC BioPharm and Medigene...
...Tarrytown, N.Y. bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Business: Cancer Allison Johnson Adicet Bio Inc. bluebird bio Inc. Celgene Corp. Medigene AG Regeneron...
BioCentury | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

...R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd. (KOSDAQ:084990), Medigene AG...
...Prime Therapeutics Inc. (NASDAQ:FPRX). Three of the deals -- those with Celgene, TC BioPharm and Medigene...
...closed a $632.5 million follow-on. Regeneron dipped $4.83 to $390.05. Allison Johnson Adicet Bio Inc. bluebird bio Inc. Celgene Corp. Medigene AG Regeneron...
Items per page:
1 - 10 of 581
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...SIX:VIFN) for about $915 million; NeuroVir Therapeutics Inc., which was taken out in 2001 by Medigene AG...
BioCentury | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

...announced Thursday that its next-generation melanoma-associated antigen A4 (MAGEA4) TCR therapy, developed in collaboration with Medigene AG...
...single agent led to "robust" antitumor activity controlling tumors in a melanoma xenograft model (see "Medigene...
...bluebird gained $1.03 to $133.52 on Thursday. Mark Zipkin, Staff Writer Zynteglo (LentiGlobin BB305 gene therapy) bluebird bio Inc. Medigene AG...
BioCentury | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

...newco also obtained a license in Asian territories to four T cell immunotherapy programs from Medigene AG...
...targets that Cytovant has yet to choose, according to Medigene CEO and CSO Dolores Schendel. Medigene...
...billion in milestones across the four programs, plus low double-digit royalties. Cytovant will also reimburse Medigene's...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...U.K.) hired Markus Dangl as CSO. He was SVP for research and non-clinical development at Medigene AG...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...Jason Cole will assume the new and expanded role of chief operating and legal officer. Medigene AG...
BioCentury | Jan 11, 2019
Company News

Medigene licenses co-stimulator from Helmholtz to overcome checkpoint blockade with TCRs

...4-1BB ligand (4-1BBL; TNFSF9; CD137L), to help T cells overcome checkpoint blockade in solid tumors. Medigene...
...disclosed. Helmholtz Zentrum München, Neuherberg, Germany Medigene AG (Xetra:MDG1), Martinsried, Germany Business: Cancer Jennie Walters Helmholtz Zentrum Muenchen GmbH Medigene AG 4-1BB...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...to see if there is any effect on lipids in peripheral blood.” Ginna Laport, Tempest Medigene AG...
...Dracen Pharmaceuticals Inc., Baltimore, Md. Genfit S.A. (Euronext:GNFT), Loos, France Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Medigene AG...
BioCentury | Aug 31, 2018
Company News

Management tracks: Medigene, Merck KGaA

...Medigene AG (Xetra:MDG1) said CFO Thomas Taapken has resigned. Medigene is seeking a successor. Taapken, who...
...successor. Taapken, who joined the cancer immunotherapy company in January 2017, will continue to advise Medigene...
BioCentury | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

...R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd. (KOSDAQ:084990), Medigene AG...
...Prime Therapeutics Inc. (NASDAQ:FPRX). Three of the deals -- those with Celgene, TC BioPharm and Medigene...
...Tarrytown, N.Y. bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Business: Cancer Allison Johnson Adicet Bio Inc. bluebird bio Inc. Celgene Corp. Medigene AG Regeneron...
BioCentury | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

...R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd. (KOSDAQ:084990), Medigene AG...
...Prime Therapeutics Inc. (NASDAQ:FPRX). Three of the deals -- those with Celgene, TC BioPharm and Medigene...
...closed a $632.5 million follow-on. Regeneron dipped $4.83 to $390.05. Allison Johnson Adicet Bio Inc. bluebird bio Inc. Celgene Corp. Medigene AG Regeneron...
Items per page:
1 - 10 of 581